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Aims The Systematic COronary Risk Evaluation (SCORE) scale assesses 10 year risk of fatal atherosclerotic cardiovascular
disease (CVD), based on conventional risk factors. The high-risk SCORE version is recommended for Central and
Eastern Europe and former Soviet Union (CEE/FSU), but its performance has never been systematically assessed in
the region. We evaluated SCORE performance in two sets of population-based CEE/FSU cohorts.
Methods
and results
The cohorts based on the WorldHealth OrganizationMONitoring of trends anddeterminants in CArdiovascular disease
(MONICA) surveys in the Czech Republic, Poland (Warsaw and Tarnobrzeg), Lithuania (Kaunas), and Russia (Novosi-
birsk) were followed from the mid-1980s. The Health, Alcohol, and Psychosocial factors in Eastern Europe (HAPIEE)
study follows Czech, Polish (Krakow), and Russian (Novosibirsk) cohorts from 2002–05. In Cox regression analyses,
the high-risk SCORE ≥5% at baseline significantly predicted CVD mortality in both MONICA [n ¼ 15 027; hazard
ratios (HR), 1.7–6.3] and HAPIEE (n ¼ 20 517; HR, 2.6–10.5) samples. While SCORE calibration was good in most
MONICA samples (predicted and observed mortality were close), the risk was underestimated in Russia. In HAPIEE,
the high-risk SCORE overpredicted the estimated 10 year mortality for Czech and Polish samples and adequately pre-
dicted it for Russia. SCORE discrimination was satisfactory in both MONICA and HAPIEE.
Conclusion The high-risk SCORE underestimated the fatal CVD risk in Russian MONICA but performed well in most MONICA
samples and Russian HAPIEE. This SCORE version might overestimate the risk in contemporary Czech and Polish popu-
lations.
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Keywords Cardiovascular mortality † Cardiovascular risk factors † SCORE risk function † Risk prediction † Central and
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Introduction
Cardiovascular disease (CVD) is the world’s leading cause of
mortality, morbidity, and disability.1,2 Numerous algorithms use
combinations of conventional risk factors to identify individuals at
higher risk of CVD, who are most likely to benefit from preventive
measures.2,3 The existing risk scores were mostly derived from
Western European and North American cohorts, and their
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prognostic accuracy might differ in other populations.4,5 The most
widely used instruments are the Framingham risk model6 and the Sys-
tematic COronary Risk Evaluation (SCORE) scale.7 The latter, based
on prospectivedata from12European cohorts, estimates10 year risk
of fatal CVD and uses age, sex, blood lipids, blood pressure, and
smoking as risk predictors. One component of the SCORE model
defines the shape of the baseline survival function, separately for
men and women, while the other calculates relative risks for each
risk factor. The effects of risk factors are considered to be similar in
both genders, across countries, and over time.7 Two SCORE ver-
sions were created for high- and low-risk European countries.
While CVD mortality has recently declined in most Central and
Eastern European (CEE) countries, it is still high in almost all of the
former Soviet Union (FSU).8 The latest guidelines by the European
Society of Cardiology (ESC) acknowledge the heterogeneity of the
background CVD risk in this region but still provide only one
version of the high-risk SCORE, recommended for use in all CEE/
FSU populations.5 It is unclear how well SCORE performs in CEE/
FSU, as it was derived without reference to the local data5 and has
never been properly recalibrated for this area.
Our studyaimed to assess the prognostic performance of the high-
risk SCORE in CEE/FSU, using two sets of population-based cohorts
from four countries in the region.
Methods
Study population and samples
We used the data from two international studies: the World Health Or-
ganization (WHO) MONitoring of trends and determinants in CVD
(MONICA) Project9,10 and the Health, Alcohol, and Psychosocial
factors in Eastern Europe (HAPIEE) study.11
The WHO MONICA Project monitored the trends in CVD rates and
risk factors in 38 populations from the mid-1980s to at least the
mid-1990s.9,10 Risk factors were assessed in random population
samples of men and women aged 35–64; some of these samples were fol-
lowed for mortality. We obtained the baseline data and the data on the
subsequent 10 year mortality from the following MONICA samples:
the Czech sample from six country districts, examined in 1992; Polish
Warsaw and Tarnobrzeg samples screened in 1983–84 and 1987–89;
Lithuanian Kaunas samples examined in 1983–85, 1986–87, and
1992–93; and Russian Novosibirsk samples screened in 1985–86,
1988–89, and 1994–95. Numbers of subjects and response rates are
presented in Table 1. At baseline, participants completed a questionnaire
survey, underwent a clinical examination, and provided a blood sample.
The mortality follow-up used the data from national and local mortality
registers.9
HAPIEE is a multi-centre study of CVD and other chronic conditions in
CEE/FSU.11 It follows random population samples of men and women,
aged 45–69 at baseline (2002–05), from the Czech Republic (Havı́řov/
Karviná, Hradec Králové, Jihlava, Kroměřı́ž, Liberec, and Ústı́ nad
Labem), Poland (Krakow), Russia (Novosibirsk), and Lithuania
(Kaunas). The four cohorts have been followed for cause-specific mortal-
ity and non-fatal CVD. As the Lithuanian cohort entered the study later
and had fewer CVD deaths, we analysed only Czech, Polish, and
Russian data. The baseline data collection included a questionnaire
surveyand aphysical examination, with a fastingvenousblood sample col-
lection. Mortality data for the median follow-up period of 4.6–6.2 years
(Table 1) come from national (the Czech Republic) and local (Poland and
Russia) registers.11
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As SCORE predicts the risk of cardiovascular mortality in individuals
over 40 and without pre-existing atherosclerotic CVD,5,7 we excluded
subjects with a self-reported history or medical evidence of myocardial
infarction, angina, or stroke and those aged ,40 years at baseline. We
also excluded individuals with missing values of the risk factors, which
are incorporated in SCORE. In Czech and Polish HAPIEE samples, the
study questionnaire was completed at home, prior to medical examin-
ation in a clinic. This explains the smaller proportion of Czech and
Polish participants with non-missing values of SCORE components.
The sizes of our analytical samples (15 027 MONICA and 20 517
HAPIEE participants) are presented in Table 1.
The MONICA study protocol was approved by the local ethics com-
mittees in each participating country.9 The HAPIEE study protocol was
approved by the UCL/UCLH ethics committee and by the local ethics
committees at each study centre.11 All participants provided informed
consent.
Measurements
The SCORE risk predictors include age, sex, smoking status, total choles-
terol (TC), and systolic blood pressure (SBP). In MONICA and HAPIEE,
the dataon self-reported smoking status came fromthe baseline standard
questionnaire.9– 11 In line with the SCORE criteria,7 participants current-
ly and regularly smoking at least one cigarette per day were regarded as
current smokers; never and ex-smokers were considered non-smokers.
SBP measurement was performed after a 5 min rest, in a quiet room with
comfortable temperature, in a sitting position, on the right arm, with a 2
min interval betweenmeasurements, using a standard mercury sphygmo-
manometer (MONICA) or a digital blood pressure monitor Omron M5-I
(HAPIEE).9,11 TC concentration in fasting venous blood was measured
with a direct Liebermann-Burchard method in Polish and Russian
MONICA and with an enzymatic method in all other samples.9,11 All
assaymethods were calibrated, and all laboratories were subjected to ex-
tensive quality control. In agreement with SCORE end-points,7 the study
outcome was coronary or non-coronary atherosclerotic cardiovascular
death.
Statistical analyses
The high-risk version of SCORE, recommended by the ESC for CEE/FSU
populations,5 was used to predict the risk of fatal atherosclerotic CVD in
all MONICA and HAPIEE samples, as the recently introduced Czech and
Polish SCORE versions lack a detailed description of their development
and recalibration.12,13 For comparison, the performance of the low-risk
SCORE was also investigated.
The prognostic performance of risk prediction scales, such as SCORE,
could be assessed via calibration and discrimination.14,15 Calibration
reflects how close predicted and observed risks are, with a
predicted-to-observed (P/O) risk ratio of 1.0 indicating perfect calibra-
tion. In our samples, particularly in female ones, a substantial proportion
of individuals had the same, relatively low risk levels; therefore, we
focused on P/O ratios as the preferred calibration measure. Discrimin-
ation is the model’s ability to separate participants who will experience
events (such as fatal CVD) during the follow-up from those who will
remain event-free. The typically used threshold measures of discrimin-
ation include sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) for a particular risk cut-off (5% for
SCORE). Summary measures of discrimination include the area under
the receiver operating characteristic curve (AUROC) and its equivalent
for survival models, Harrell’s C-statistic.16 AUROC plots the model’s
sensitivity against ‘1—specificity’ across all consecutive cut-offs.
AUROC/C-statistic values of 0.5 and 1.0 indicate minimal and ideal dis-
crimination, respectively.
Our analyses of SCORE prognostic ability were performed separately
for men and women in each MONICA and HAPIEE sample and included
the following steps. First, we investigated the role of SCORE as a fatal
CVD predictor, using Cox regression models. Second, we assessed
SCORE calibration, calculating P/O risk ratios for MONICA. For
HAPIEE, we estimated 10 year levels of atherosclerotic CVD mortality
and compared SCORE levels to these estimates, in order to approximate
the 10 year SCORE calibration. Finally, we assessed SCORE discrimin-
ation by calculating its sensitivity, specificity, PPV, NPV, and Harrell’s C.
The use of Cox proportional hazards regression models was justified
by the high P-values in Schoenfeld’s test across all the samples. The data
from all MONICA waves were pooled within samples, because the
SCORE-fatal CVD association showed no evidence of confounding by
or statistical interaction with the study wave. The estimation of 10 year
CVD mortality for HAPIEE was based on the mortality patterns in
MONICA samples from respective countries. We assumed that the
ratio between the death numbers registered at a pre-specified cut-off
point (the follow-up time in complete years: six, five, and four years for
Czech, Polish, and Russian HAPIEE, respectively) and the death
numbers observed during the 10 year follow-up would be similar for
MONICA and HAPIEE subjects from the same country. These ratios
were separately calculated for Czech, Polish (Warsaw), and Russian
MONICA men and women and projected onto the currently observed
numbers of cardiovascular deaths in HAPIEE samples, in order to
provide estimates of the 10 year CVD mortality. These estimates were
then used for the analyses of the expected 10 year SCORE calibration
in HAPIEE. Two-sided P-values ,0.05 were used to indicate statistical
significance. All statistical analyses were performed using Stata/IC 11.0
(StataCorp LP, Texas, USA).
Results
Baseline sample characteristics are presented in Table 2. The mean
age of MONICA participants was close to 52 years, compared with
57 years in HAPIEE. In both studies, the sizes of the five-year age
groups were relatively similar. Smoking prevalence was high in both
studies, with the exception of MONICA women from Tarnobrzeg,
Kaunas, and Novosibirsk. Czech and Polish HAPIEE men smoked
less than their MONICA peers. In contrast, among Russian women,
smoking prevalence was higher in HAPIEE than in MONICA. In
both studies, mean TC levels were close to 6 mmol/L and tended
to be slightly higher in women. The highest mean SBP levels, exceed-
ing 140 mm Hg, were observed for MONICA participants from
Warsaw and Czech HAPIEE men.
SCORE as a CVD mortality predictor
In mostMONICAsamples, the high-risk SCORE≥5% atbaselinewas
significantly associated with the 10 year risk of atherosclerotic CVD
mortality (Figure 1). The hazard ratios (HR) varied from 1.7 in
Warsaw women to 6.3 in women from Novosibirsk. In HAPIEE,
the baseline SCORE was a significant predictor of fatal CVD over
the subsequent 4.5–6 years (HR, 2.6–10.5).
SCORE calibration
In all male MONICA samples, mean SCORE-predicted risk levels
were relatively high (≥5%); for women, predicted risk was consider-
ably lower and approached 2% (Table 3). Among MONICA men, the
percentage of atherosclerotic CVD deaths registered over 10 years
was highest in Novosibirsk and lowest in Kaunas. In women, the
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observed risk of fatal CVD was half of that in men from the respective
samples. While most ratios of predicted and observed (P/O) CVD
mortality were close to 1.0, the risk was markedly underestimated
for Russian men and women.
In each male HAPIEE sample, mean predicted levels of 10 year fatal
CVD exceeded 5%; in women, the predicted risk was three times
lower. The percentage of CVD deaths registered in Russian men
was two to three times higher than among their Czech and Polish
peers; the observed cardiovascular mortality levels in women were
lower but reflected the same ranking. For the currently available
data on fatal CVD, all P/O ratios exceeded 1.0, while the magnitude
of risk overprediction was smaller for Russian vs. Czech and Polish
HAPIEE.
As SCORE predicts the 10 year risk of atherosclerotic cardiovas-
cular mortality, we estimated the expected 10 year levels of fatal
CVD, in order to assess SCORE calibration in HAPIEE. The estimated
percentage of deaths for Czech and Polish HAPIEE was noticeably
lower than the 10 year mortality levels for the respective
MONICA samples. In contrast, the estimated percentage for
Russian HAPIEE was slightly higher than the fatal CVD levels in
Russian MONICA (Table 3). This difference possibly reflects the het-
erogeneous CVD trends across CEE/FSU in the last two decades.8 In
agreement with the currentdiscrepancies betweenRussian vs. Czech
and Polish national mortality rates,8 our fatal CVD estimates were at
least three times higher in Russian HAPIEE participants than in their
Czech and Polish peers. Based on the ratios of predicted-
to-estimated (P/E) mortality (Table 3), the high-risk SCORE demon-
strated at least a two-fold overprediction of the estimated mortality
for Czech and Polish HAPIEE, while the agreement between the pre-
dicted and estimated risk was good for Russian HAPIEE. The low-risk
SCORE version also overpredicted 10 year estimated mortality in
Czech and Polish HAPIEE (respective P/E ratios 1.2–1.4; see Supple-
mentary material online, Table), but to a lesser extent than the
high-risk SCORE. Among Russian participants, the low-risk SCORE
predicted only one-half of the estimated mortality (P/E ratios 0.5–
0.6; see Supplementary material online, Table).
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Table 2 Sample characteristics
Categories MONICA men HAPIEE men
CZ PL-W PL-T LT RU CZ PL-K RU
N 636 1253 1267 1651 2576 2659 3456 3246
Mean age (SD), years 50.8 (7.1) 51.9 (7.0) 52.5 (6.8) 51.3 (7.1) 52.3 (6.8) 58.0 (7.1) 57.2 (7.0) 57.5 (7.0)
Age groups, %
40–44 27.0 21.6 17.4 23.8 17.7 — — —
45–49 22.5 20.8 20.8 19.3 22.6 17.3 20.4 18.9
50–54 21.1 20.0 21.6 18.1 20.8 19.6 21.7 21.3
55–59 15.9 22.5 23.2 22.9 23.1 20.7 21.4 21.6
60–64 13.5 15.1 17.0 15.9 15.8 21.6 18.3 18.2
65+ — — — — — 20.8 18.2 20.0
Current smoking, % 40.3 52.5 56.3 35.1 53.1 26.6 32.9 51.0
Mean TC (SD), mmol/L 6.2 (1.3) 5.6 (1.0) 5.5 (1.0) 6.0 (1.2) 5.5 (1.2) 5.7 (1.0) 5.8 (1.1) 6.0 (1.2)
Mean SBP (SD), mm Hg 139.0 (20.7) 142.2 (23.8) 136.6 (21.2) 137.3 (20.0) 136.3 (20.2) 143.8 (18.4) 141.6 (20.2) 141.6 (22.7)
MONICA women HAPIEE women
CZ PL-W PL-T LT RU CZ PL-K RU
N 704 1151 1462 1650 2677 3359 3753 4044
Mean age (SD), years 51.2 (7.2) 51.8 (7.0) 52.4 (6.9) 50.9 (7.1) 52.2 (7.0) 57.4 (7.1) 56.6 (6.9) 57.3 (7.1)
Age groups, %
40–44 24.0 21.8 18.3 24.6 19.4 — — —
45–49 24.9 21.6 21.6 21.0 22.0 19.6 22.8 20.6
50–54 17.6 20.4 21.4 19.6 20.8 21.2 23.4 20.8
55–59 18.2 20.9 21.1 19.3 20.5 18.2 20.6 21.8
60–64 15.3 15.3 17.6 15.5 17.3 23.7 17.7 17.2
65+ — — — — — 17.3 15.5 19.6
Current smoking, % 20.6 31.2 7.5 4.2 3.4 21.0 25.1 10.1
Mean TC (SD), mmol/L 6.3 (1.3) 5.7 (1.0) 5.7 (1.1) 6.3 (1.2) 5.9 (1.3) 5.9 (1.0) 5.9 (1.1) 6.5 (1.3)
Mean SBP (SD), mm Hg 137.7 (21.7) 142.6 (25.1) 141.6 (24.3) 137.3 (22.7) 138.5 (22.6) 134.2 (19.4) 133.2 (20.8) 141.6 (25.7)
CZ, Czech Republic; LT, Lithuania; PL-K, Poland (Krakow); PL-T, Poland (Tarnobrzeg); PL-W, Poland (Warsaw); RU, Russia. SBP, systolic blood pressure; SD, standard deviation;
TC, total cholesterol.
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SCORE discrimination
Sensitivity of the high-risk SCORE was relatively high in all male
MONICA and HAPIEE samples, whereas its specificity was some-
what lower; the opposite was true for MONICA and HAPIEE
women (Table 3). Due to the low outcome frequency, PPV values
were also low across all the samples; in contrast, NPV values
exceeded 0.9. All Harrell’s C-values were over 0.50 and were
highest for Czech men and Russian women in MONICA and for
Czech men and Polish women in HAPIEE. A direct comparison of
SCORE discrimination in MONICA vs. HAPIEE was not possible,
due to the current difference in the follow-up length. However,
SCORE sensitivity appeared higher and specificity lower for most
HAPIEE samples, compared with respective MONICA samples.
Discussion
To the best of our knowledge, this is the first attempt to assess the
SCORE prognostic performance in CEE/FSU. As expected, the high-
risk SCORE was a significant risk predictor in both MONICA and
HAPIEE samples, which are the best available approximations of
the national levels of cardiovascular risk factors and fatal CVD for
the 1980s to 2000s. SCORE calibration was good in MONICA,
with the exception of Russia where fatal CVD was substantially
underpredicted. This primarily reflects the very high baseline risk:
Russia is now regarded by the ESC as a ‘very-high-risk country’, al-
though no relevant SCORE version has yet been provided.5 It is
also possible that the very high mortality risk in Russian MONICA
was partly influenced by the recent mortality fluctuations.8 In
HAPIEE, the comparison between the estimated 10 year CVD mor-
tality and the SCORE predictions demonstrated that better calibra-
tion was achieved by the high-risk SCORE for Russian samples and
the low-risk SCORE for Czech and Polish samples. The high-risk
SCORE discrimination was satisfactory in MONICA and HAPIEE.
Strengths and limitations
Several methodological issues need to be considered when inter-
preting our findings. First, we used the data from two separate
studies, which covered different historical periods. As CVD trends
in CEE/FSU have diverged after 1990, and Russian cardiovascular
mortality levels have shown large temporal fluctuations, the cohort
study estimates of a longer-term mortality risk may be an imperfect
approximation of national rates. Second, while the participating
cohorts are not nationally representative, they are the best available
sources of data, and their ranking by fatal CVD levels reflects
between-country differences in cardiovascular mortality. Third,
due to a shorter follow-up, the 10 year risk of CVD death in
Figure 1 The high-risk SCORE (≥5 vs. ,5%) and atherosclerotic cardiovascular mortality in MONICA and HAPIEE men (A) and women (B)
hazard ratios (HR) and 95% confidence intervals (CI). CZ, Czech Republic; LT, Lithuania; PL-K, Poland (Krakow); PL-T, Poland (Tarnobrzeg);
PL-W, Poland (Warsaw); RU, Russia.
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HAPIEE was estimated. We compared two estimation approaches—
one based on the MONICA patterns of cardiovascular mortality and
the other based on the exponential survival model17 (not shown)—
which produced similar results. Fourth, the comparability of
MONICA and HAPIEE data was high, as the protocols of baseline
survey, physical examination, and mortality follow-up were similar.
Fifth, as in most studies, MONICA and HAPIEE participants were
likely tobehealthier thannon-responders.This potential discrepancy
could be enhanced by the complete case analyses and dilute the as-
sociation of interest. The available multiple imputation methods
employ the assumption of data missing (completely) at
random,18,19 which was not the case for our samples. Moreover,
the Cox regression results across the samples with the highest
SCORE missingness were similar for complete and multiply-imputed
data (not presented). Sixth, some context-specific misclassification
of outcomes within the broad category of atherosclerotic CVD
deaths might occur, but it was unlikely to affect the associations of
interest. Finally, SCORE, like most other risk scales, provides risk
point estimates without confidence intervals and does not account
for SBP and TC regression to the mean or for CVD treatment
effects. However, this single-estimate approach is user-friendly and
clinically applicable.
Consistency with other studies
The validity of our results, despite the above-mentioned potential
limitations, is supported by the fact that the levels of major risk
factors and CVD mortality in MONICA and HAPIEE samples were
consistent with the respective national cross-sectional estimates
and trends, presented in the WHO Global InfoBase20 and WHO sys-
tematic reviews.21,22 The association between baseline SCORE and
fatal CVD was statistically significant in both MONICA and
HAPIEE. To the best of our knowledge, only two other studies
have reported the magnitude of the SCORE–CVD association. For
middle-aged Austrians, the strength of a significant link between con-
tinuous SCORE and 10 year CVD mortality was reported only after
adjustment for several covariates.23 Among adults participating in the
Greek ATTICA study, HellenicSCORE levels were significantly asso-
ciated with the five-year risk of incident CVD.24 While the direct
comparison of these results is problematic, the reported HR
values23,24 are close to the estimates for high-risk continuous
SCORE in MONICA and HAPIEE (not presented).
It is difficult to compare our findings on SCORE calibration to
other CEE/FSU data, due to the above-mentioned lack of similar
local studies. However, our results are consistent with the evidence
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Table 3 Prognostic performance of the high-risk SCORE (≥5 vs. <5%)
MONICA men HAPIEE men
CZ PL-W PL-T LT RU CZ PL-K RU
Predicted (P) deaths, N (%) 33.5 (5.26) 72.4 (5.78) 69.0 (5.43) 83.1 (5.03) 138.1 (5.36) 199.7 (7.51) 254.7 (7.37) 294.4 (9.07)
Observed (O) deaths, N (%) 32 (5.03) 86 (6.68) 62 (4.89) 58 (3.51) 181 (7.03) 37 (1.39) 34 (0.98) 105 (3.23)
P/O ratio 1.05 0.87 1.11 1.43 0.76 5.40 7.52 2.81
Estimated (E) deaths, N (%)* — — — — — 74.0 (2.78) 94.2 (2.73) 279.3 (8.60)
P/E ratio — — — — — 2.70 2.70 1.06
Sensitivity 0.78 0.79 0.71 0.72 0.65 0.95 0.79 0.94
Specificity 0.59 0.54 0.56 0.60 0.58 0.37 0.39 0.33
PPV 0.09 0.11 0.08 0.06 0.11 0.02 0.01 0.05
NPV 0.98 0.97 0.97 0.98 0.96 0.99 0.99 0.99
Harrell’s C 0.69 0.67 0.63 0.67 0.62 0.66 0.60 0.63
MONICA women HAPIEE women
CZ PL-W PL-T LT RU CZ PL-K RU
Predicted (P) deaths, N (%) 12.5 (1.78) 22.6 (1.96) 24.6 (1.68) 26.4 (1.60) 44.7 (1.67) 85.0 (2.53) 92.0 (2.45) 124.6 (3.08)
Observed (O) deaths, N (%) 13 (1.85) 21 (1.82) 19 (1.30) 26 (1.58) 86 (3.21) 19 (0.57) 16 (0.43) 42 (1.04)
P/O ratio 0.96 1.08 1.29 1.01 0.52 4.44 5.70 2.96
Estimated (E) deaths, N (%)* — — — — — 41.2 (1.23) 37.3 (0.99) 139.0 (3.44)
P/E ratio — — — — — 2.06 2.48 0.90
Sensitivity 0.39 0.19 0.26 0.31 0.37 0.42 0.63 0.71
Specificity 0.89 0.88 0.92 0.92 0.92 0.83 0.84 0.76
PPV 0.06 0.03 0.04 0.06 0.13 0.01 0.02 0.03
NPV 0.99 0.98 0.99 0.99 0.98 0.99 0.99 0.99
Harrell’s C 0.64 0.54 0.59 0.61 0.64 0.63 0.74 0.74
CZ, Czech Republic; LT, Lithuania; PL-K, Poland (Krakow); PL-T, Poland (Tarnobrzeg); PL-W, Poland (Warsaw); RU, Russia. CI, confidence interval; HR, hazard ratio; NNP, negative
predictive value; PPV, positive predictive value.
*MONICA-based estimations of 10 year CVD mortality in HAPPIEE.
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from Western studies, which suggest that original and recalibrated
SCORE versions tend to overpredict risk in populations with declin-
ing CVD rates.23,25– 27 Our data on SCORE discrimination also agree
with the results for Western populations. In particular, similar to the
findings for MONICA and HAPIEE men, SCORE sensitivity was
higher than its specificity across the high-risk SCORE Project
cohorts7 and among middle-aged Belgians.28 In agreement with our
results for MONICA and HAPIEE women, lower sensitivity and
higher specificity of SCORE were demonstrated for the low-risk
SCORE Project cohorts7 and in middle-aged adults from Finland,29
Iceland,25 Spain,30 and Austria.23 Low SCORE PPVs were observed
notonly inMONICAandHAPIEEbut also inmiddle-aged Spaniards30
and Austrians.23 The Harrell’s C-values in MONICA and HAPIEE
were close to AUROC values reported for the high- and low-risk
SCORE Project cohorts7 and middle-aged adults from Norway,26
Iceland,25 and Austria.23 However, only in two of our samples
(Polish and Russian HAPIEE women), Harrell’s C-values exceeded
0.70, which suggests only moderate discrimination.
To summarize, the high-risk SCORE was a significant predictor of
fatal atherosclerotic CVD in MONICA and HAPIEE, but it underpre-
dicted the risk in Russian MONICA and could overestimate the risk in
Czech and Polish HAPIEE. These findings have several implications.
First, the high-risk SCORE can be still used for populations with
high cardiovascular mortality levels, such as Russia. For countries
where fatal CVD is declining, such as the Czech Republic and
Poland, the low-risk SCORE might be preferable. A longer-term so-
lution is SCORE recalibration for specificCEE/FSU populations, using
local levels of CVD mortality and risk factors. Second, SCORE per-
formance might benefit from the model’s extension by additional
risk determinants,31– 33 such as socioeconomic parameters or haz-
ardous drinking characteristics. Third, our study has reemphasized
the importance of conventional risk factors for CVD prediction
and prevention. Controlling these factors in higher-risk groups and
individuals and across whole populations will reduce the burden of
CVD in CEE/FSU and prevent the reversal of declining CVD rates
elsewhere.3,5,34 Finally, as demonstrated bya steadydecline in cardio-
vascular mortality across most Western populations over the last 50
years and, more recently, by the positive dynamic of Czech and Polish
CVD trends,8 the task of reducing CVD burden in CEE and particu-
larly FSU is challenging but nonetheless feasible.
Supplementary material
Supplementary material is available at European Heart Journal online.
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